Skip to main content
single10MG

Oxytocin

10MG Protocol

Oxytocin 10MG

Injection Freq.

Inject once daily

Cycle Sched.

8–12 weeks; optional extension to 16 weeks

Reconstitution

3.0 mL BAC water

Increased trust/social bonding
reduced social anxiety (research association)
Investigated for autism spectrum disorder and social-cognition effects
Explored in PTSD, depression, and addiction research as an adjunct
Reduced caloric intake and increased fat oxidation reported in studies
Modest weight-loss, improved insulin sensitivity, and reduced visceral fat signals in small trials
Analgesic and anti-inflammatory effects
local pain reduction after SC dosing described
Reproductive smooth-muscle effects (uterotonic biology reminder)
1

Reconstitution Requirements

  • 3.0 mL BAC water
StepWeek RangeDoseUnits
1Weeks 1–2100 mcg3
2Weeks 3–4200 mcg6
3Weeks 5–6300 mcg9
4Weeks 7–8400 mcg12
5Weeks 9–12500 mcg15

Inject once daily

8–12 weeks; optional extension to 16 weeks

Oxytocin works by binding to oxytocin receptors (OXTR), a G-protein–coupled receptor expressed across central and peripheral tissues. In the brain, oxytocin functions as a neuromodulator: it is produced in the hypothalamus and released both into the circulation and within neural circuits that shape emotion and social behavior. The protocol describes central OXTR activation as influencing neurotransmitter systems (including dopamine-linked prosocial signaling) and dampening stress reactivity through the hypothalamic–pituitary–adrenal axis, mechanisms linked to observed effects on trust, bonding, empathy, and social anxiety. Peripherally, oxytocin contracts smooth muscle (e.g., uterine contraction and milk ejection) and may influence pain and inflammation; the page cites evidence for local analgesic effects after subcutaneous administration. Importantly, it does not cross the blood–brain barrier well from blood, so route of administration shapes the primary target (peripheral vs central engagement).
Not listed on page (the page reports a placebo-like safety profile and no reliable side effects at studied intranasal doses)
  • Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
  • Add diluent slowly down the vial wall to minimize foaming
  • Gently swirl/roll until fully dissolved (do not shake)
  • Label vial with reconstitution date and concentration; protect from light
  • Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
  • Avoid repeated freeze–thaw cycles
  • Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
  • Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)